BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29335924)

  • 1. BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Jakimovska M; Maleva Kostovska I; Popovska-Jankovic K; Kubelka-Sabit K; Karadjozov M; Stojanovska L; Arsovski A; Smichkoska S; Lazarova E; Jakimovska Dimitrovska M; Plaseska-Karanfilska D
    Breast Cancer Res Treat; 2018 Apr; 168(3):745-753. PubMed ID: 29335924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
    Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
    Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
    Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
    BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
    Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
    Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    Dodova RI; Mitkova AV; Dacheva DR; Hadjo LB; Vlahova AI; -Hadjieva MST; Valev SS; Caulevska MM; Popova SD; Popov IE; Dikov TI; Sedloev TA; Ionkov AS; Timcheva KV; Christova SL; Kremensky IM; Mitev VI; Kaneva RP
    BMC Cancer; 2015 Jul; 15():523. PubMed ID: 26183948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
    BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
    Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    Cao WM; Gao Y; Yang HJ; Xie SN; Ding XW; Pan ZW; Ye WW; Wang XJ
    BMC Cancer; 2016 Feb; 16():64. PubMed ID: 26852015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.
    Schmidt AY; Hansen TVO; Ahlborn LB; Jønson L; Yde CW; Nielsen FC
    J Mol Diagn; 2017 Nov; 19(6):809-816. PubMed ID: 28822785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
    Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
    Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
    Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.